"Il Pascale è il maggiore IRCCS Oncologico del Mezzogiorno ed è Centro di Riferimento per la rete oncologica nazionale e regionale. L'Istituto persegue finalità di ricerca prevalentemente clinica, e di ricerca applicata nel campo biomedico e in quello dell'organizzazione e gestione dei servizi sanitari, dedicando grande impegno alle problematiche più ampie del paziente oncologico, che vanno dall'assistenza psicologica ai problemi nutrizionali, alla terapia del dolore, alle cure palliative in genere, fino alle fasi più delicate della malattia."

During the past decade, IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"" #1 sponsor was "Bristol-Myers Squibb" with 2 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 2 trials sponsored, "University of Campania "Luigi Vanvitelli"" with 2 trials sponsored, "Aileron Therapeutics, Inc." with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"" are "Breast Cancer" (1 trials), "Cancer of the Prostate" (1 trials), "Carcinoma, Squamous Cell of Head and Neck" (1 trials), "Colorectal Cancer Stage IV" (1 trials) and "Head and Neck Cancer" (1 trials). Many other conditions were trialed in "IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"" in a lesser frequency.

Most popular intervention types in "IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"" are "Drug" (9 trials), "Biological" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "ALRN-6924" (1 trials), "Afatinib" (1 trials), "Avelumab" (1 trials) and "Carboplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"" are 9 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale"". 1 are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale", undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale", 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".